Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, MarketBeat.com reports. ...

HAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of...

Fisher Asset Management LLC lowered its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 5.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the...

American Century Companies Inc. grew its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 24.7% during the second quarter, according to the company in its most recent filing with the Securitie...

HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished...

HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:...

Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU...